Targeted Nanoparticle Delivery of Bifunctional RIG-I Agonists to Pancreatic Cancer.
作者信息
Zillinger Thomas, Hartmann Gunther
机构信息
Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital, University of Bonn, Bonn, Germany.
Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital, University of Bonn, Bonn, Germany.
出版信息
Mol Ther. 2019 Mar 6;27(3):491-492. doi: 10.1016/j.ymthe.2019.02.005. Epub 2019 Feb 20.
Abstract
摘要
相似文献
1
Targeted Nanoparticle Delivery of Bifunctional RIG-I Agonists to Pancreatic Cancer.
Mol Ther. 2019 Mar 6;27(3):491-492. doi: 10.1016/j.ymthe.2019.02.005. Epub 2019 Feb 20.
2
Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer.
Mol Ther. 2019 Mar 6;27(3):507-517. doi: 10.1016/j.ymthe.2018.11.012. Epub 2018 Nov 17.
3
IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
ACS Nano. 2015 Aug 25;9(8):7976-91. doi: 10.1021/acsnano.5b01288. Epub 2015 Aug 10.
4
Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression.
J Control Release. 2016 Jun 28;232:131-42. doi: 10.1016/j.jconrel.2016.03.023. Epub 2016 Apr 2.
5
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.
Cancer Res. 2013 Mar 15;73(6):1709-20. doi: 10.1158/0008-5472.CAN-11-3850. Epub 2013 Jan 21.
6
Nanoparticle formulation of ormeloxifene for pancreatic cancer.
Biomaterials. 2015;53:731-43. doi: 10.1016/j.biomaterials.2015.02.082. Epub 2015 Mar 26.
7
Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
J Biomed Mater Res A. 2015 Apr;103(4):1476-84. doi: 10.1002/jbm.a.35286. Epub 2014 Aug 4.
8
Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas.
Bioconjug Chem. 2006 Jul-Aug;17(4):905-11. doi: 10.1021/bc060035+.
9
Ultrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded mPEG-PLGA-PLL Nanoparticles in Pancreatic Cancer.
Theranostics. 2016 Jun 18;6(10):1573-87. doi: 10.7150/thno.15164. eCollection 2016.
10
Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.
Int J Nanomedicine. 2014 Dec 3;9:5653-65. doi: 10.2147/IJN.S68511. eCollection 2014.
引用本文的文献
1
Activation of Immune Responses Through the RIG-I Pathway Using TRITC-Dextran Encapsulated Nanoparticles.
Immune Netw. 2024 Dec 24;24(6):e44. doi: 10.4110/in.2024.24.e44. eCollection 2024 Dec.
2
Retinoic Acid-Inducible Gene I Activation Inhibits Human Respiratory Syncytial Virus Replication in Mammalian Cells and in Mouse and Ferret Models of Infection.
J Infect Dis. 2022 Dec 13;226(12):2079-2088. doi: 10.1093/infdis/jiac295.
3
Eukaryotic Translation Initiation Factor 3 Subunit B Is a Promoter in the Development and Progression of Pancreatic Cancer.
Front Oncol. 2021 Apr 29;11:644156. doi: 10.3389/fonc.2021.644156. eCollection 2021.
4
Immunostimulatory biomaterials to boost tumor immunogenicity.
Biomater Sci. 2020 Oct 21;8(20):5516-5537. doi: 10.1039/d0bm01183e. Epub 2020 Sep 2.
5
RIG-I Promotes Cell Death in Hepatocellular Carcinoma by Inducing M1 Polarization of Perineal Macrophages Through the RIG-I/MAVS/NF-κB Pathway.
Onco Targets Ther. 2020 Sep 3;13:8783-8794. doi: 10.2147/OTT.S258450. eCollection 2020.
本文引用的文献
1
Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer.
Mol Ther. 2019 Mar 6;27(3):507-517. doi: 10.1016/j.ymthe.2018.11.012. Epub 2018 Nov 17.
2
Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.
Oncotarget. 2018 Jun 22;9(48):29007-29017. doi: 10.18632/oncotarget.25626.
3
The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy.
Transl Res. 2017 Dec;190:51-60. doi: 10.1016/j.trsl.2017.08.004. Epub 2017 Aug 31.
4
Targeting Nanocarriers with Anisamide: Fact or Artifact?
Adv Mater. 2017 Feb;29(7). doi: 10.1002/adma.201603451. Epub 2016 Nov 25.
5
Translating nucleic acid-sensing pathways into therapies.
Nat Rev Immunol. 2015 Sep 15;15(9):529-44. doi: 10.1038/nri3875. Epub 2015 Aug 21.
6
Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates.
Nature. 2014 Oct 16;514(7522):372-375. doi: 10.1038/nature13590. Epub 2014 Aug 10.
7
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.
Cancer Res. 2013 Mar 15;73(6):1709-20. doi: 10.1158/0008-5472.CAN-11-3850. Epub 2013 Jan 21.
8
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.
J Clin Invest. 2009 Aug;119(8):2399-411. doi: 10.1172/JCI37155. Epub 2009 Jul 20.
9
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus.
Immunity. 2009 Jul 17;31(1):25-34. doi: 10.1016/j.immuni.2009.05.008. Epub 2009 Jul 2.
10
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma.
Nat Med. 2008 Nov;14(11):1256-63. doi: 10.1038/nm.1887. Epub 2008 Nov 2.
Zotero 插件